Melissa Epperly

Melissa Epperly

Director/Board Member at NAUTILUS BIOTECHNOLOGY, INC.

Net worth: 561 386 $ as of 2026-09-29

49 year
Health Technology
Finance
Consumer Services

Profile

Melissa B. Epperly is currently an Independent Director at Roivant Sciences Ltd. since 2022, a Director at Nautilus Subsidiary, Inc., an Independent Director at Nautilus Biotechnology, Inc. since 2021, and a Trustee at The Andalusia Foundation.
Former roles include Independent Director at Kinnate Biopharma, Inc. from 2020 to 2024, Treasurer, Chief Financial & Accounting Officer at Zentalis Pharmaceuticals, Inc. from 2019 to 2024, Chief Financial Officer at Akamis Bio Ltd. from 2018 to 2019, CFO & Head-Business Development at R-Pharm US LLC from 2015 to 2018, Director at Anchorage Capital Group LLC from 2012 to 2015, Analyst at Goldman Sachs & Co. LLC from 2010 to 2012, and Research Analyst at Goldman Sachs International.
Education includes an undergraduate degree from the University of Virginia and an MBA from Harvard Business School.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2026-10-22 15,351 ( 0% ) 561 386 $ 2026-09-29
2026-06-17 0 ( -.--% ) - $ 2026-09-29

Melissa Epperly active positions

CompaniesPositionStart
NAUTILUS BIOTECHNOLOGY, INC. Director/Board Member 2021-06-08
ROIVANT SCIENCES LTD. Director/Board Member 2022-06-28
Director/Board Member -
Director/Board Member -

Former positions of Melissa Epperly

CompaniesPositionEnd
ZENTALIS PHARMACEUTICALS, INC. Director of Finance/CFO 2024-04-04
KINNATE BIOPHARMA INC. Director/Board Member 2024-04-02
Director of Finance/CFO 2019-07-31
Director of Finance/CFO 2018-05-31
Director/Board Member 2015-08-31
See the detail of Melissa Epperly's experience

Education of Melissa Epperly

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

89

1st degree connections

13

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies13

Finance

Finance

Health Technology

Consumer Services

Finance

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Technology Services

Health Technology

Commercial Services

  1. Stock Market
  2. Insiders
  3. Melissa Epperly